
|Articles|June 5, 2014
Research into MPDL3280A for the Treatment of Lung Cancer
Author(s)David Spigel, MD
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
Advertisement
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































